Keywords: unprecedented, svr24, boceprevir, schering-plough, reported, data, phase
"Unprecedented" 75% SVR24 for boceprevir
Article | 01 December 2008
Schering-Plough reported data from a Phase II study showing that a 48-week boceprevir regimen achieved an unprecedented 75% sustained virologic response ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
